Northwest Biotherapeutics plans US manufacturing restart to expand production capacity
NWBO•Northwest Biotherapeutics plans to restart US manufacturing to supplement or back up UK capacity under its Oct. 26, 2026, expansion strategy. The company also plans staffing changes in the US and UK and preparations for trials in cancers beyond brain cancer.
1. Manufacturing and staffing plans
Northwest Biotherapeutics plans to restart US manufacturing to supplement or back up UK capacity. It also cited preparations for clinical trials in cancers beyond brain cancer as an operational priority. US staffing changes are expected to increase headcount overall while keeping operating costs in the same range; one position has been eliminated, and further US cuts may target skills no longer needed. A similar UK review will expand expertise for priority operations and scale-up while reducing other personnel.
